학술논문
Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B.
Document Type
Academic Journal
Author
Razafindrazoto CI; Department of Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar.; Faculty of Medicine, University of Antananarivo, Madagascar.; Rabenjanahary TH; Department of Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar.; Faculty of Medicine, University of Antananarivo, Madagascar.; Rakotozafindrabe ALR; Department of Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar.; Faculty of Medicine, University of Antananarivo, Madagascar.; Rakotondrasoa SR; Faculty of Medicine, University of Antananarivo, Madagascar.; Randriamifidy NH; Department of Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar.; Rasolonjatovo AS; Department of Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar.; Faculty of Medicine, University of Antananarivo, Madagascar.; Razafimahefa SH; Department of Hepato-Gastroenterology, University Hospital Andrainjato, Fianarantsoa, Madagascar.; Faculty of Medicine, University of Fianarantsoa, Madagascar.; Ramanampamonjy RM; Department of Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar.; Faculty of Medicine, University of Antananarivo, Madagascar.
Source
Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: eCollection Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Accessibility of full dose daily of tenofovir disoproxil fumarate (TDF) is limited in Madagascar with an estimated cost well above the purchasing power of Malagasy population.
Objective: The study is aimed at evaluating the efficacy and safety of low-dose tenofovir for the treatment of chronic hepatitis B (CHB).
Methods: This prospective cohort study from January 2018 to December 2020 was conducted in the Department of Hepato-Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar. The patients enrolled in the study received low dose of TDF 900 mg/week (300 mg daily, three days per week).
Results: A total of 45 patients (male/female: 31/14) were included. The mean age was 45.1 ± 11.5 years. Fifteen patients were nucleos(t)ide (NA)-naïve, and 30 patients had prior NA therapy (NA-experienced). Thirty patients were HBeAg positive. A complete virological response (CVR) was achieved in 36/45 patients (80%) at 3 months, 41/45 (91.1%) at 6 months, and 43/45 (95.6%) at 12 months. High viral load at baseline was negative predictive factor of CVR at 3 months (HR: 0.14; 95% CI: 0.022-0.92; p : 0.041). There was no significant difference in response between HBeAg-positive and HBeAg-negative patients, NA-naïve and NA-experienced patients, and cirrhotic and noncirrhotic patients. Low dose of tenofovir was well tolerated. Ten patients (22.22%) had mild side effects. Mild renal failure was observed in 3 patients (6.7%) during follow-up.
Conclusion: Low dose of tenofovir is effective, safe, and well tolerated in a Malagasy population sample. These results still require verification in a large population.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2022 Chantelli Iamblaudiot Razafindrazoto et al.)
Objective: The study is aimed at evaluating the efficacy and safety of low-dose tenofovir for the treatment of chronic hepatitis B (CHB).
Methods: This prospective cohort study from January 2018 to December 2020 was conducted in the Department of Hepato-Gastroenterology, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar. The patients enrolled in the study received low dose of TDF 900 mg/week (300 mg daily, three days per week).
Results: A total of 45 patients (male/female: 31/14) were included. The mean age was 45.1 ± 11.5 years. Fifteen patients were nucleos(t)ide (NA)-naïve, and 30 patients had prior NA therapy (NA-experienced). Thirty patients were HBeAg positive. A complete virological response (CVR) was achieved in 36/45 patients (80%) at 3 months, 41/45 (91.1%) at 6 months, and 43/45 (95.6%) at 12 months. High viral load at baseline was negative predictive factor of CVR at 3 months (HR: 0.14; 95% CI: 0.022-0.92; p : 0.041). There was no significant difference in response between HBeAg-positive and HBeAg-negative patients, NA-naïve and NA-experienced patients, and cirrhotic and noncirrhotic patients. Low dose of tenofovir was well tolerated. Ten patients (22.22%) had mild side effects. Mild renal failure was observed in 3 patients (6.7%) during follow-up.
Conclusion: Low dose of tenofovir is effective, safe, and well tolerated in a Malagasy population sample. These results still require verification in a large population.
Competing Interests: The authors declare no conflicts of interest.
(Copyright © 2022 Chantelli Iamblaudiot Razafindrazoto et al.)